Item 7.01. Regulation FD Disclosure.

On December 23, 2019, Progenics Pharmaceuticals, Inc. (the "Company") issued a press release announcing top line results from the Phase 3 CONDOR trial evaluating the diagnostic performance and clinical impact of PyLTM (18F-DCFPyL) in men with biochemical recurrence of prostate cancer. PyL is the Company's PSMA-targeted small molecule positron emission tomography (PET) imaging agent designed to visualize prostate cancer. A copy of the press release is attached hereto as Exhibit 99.1 and is hereby incorporated by reference.

The information contained in this Item 7.01, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act") or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.




Item 9.01       Financial Statements and Exhibits



(d)     Exhibits.





Exhibit
  No.      Description

 99.1        Press Release announcing results of Phase 3 CONDOR Trial of PyLTM in
           prostate cancer, dated December 23, 2019

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses